Evaluation of the Thiazide Challenge Test to Differentiate Primary From Hypercalciuria-Related Hyperparathyroidism
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae239 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Ewout Verly und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Unit for Osteoporosis and Metabolic Bone Diseases, Ghent University Hospital, 9000 Ghent, Belgium. Hauptthemen laut MEDLINE: Hyperparathyroidism, Primary, Hypercalciuria, Thiazides, Hyperparathyroidism, Secondary. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Context
Treatment of primary hyperparathyroidism (PHPT) and secondary hyperparathyroidism due to idiopathic hypercalciuria (SHPT-IH) is markedly different. Robust diagnostic tools to differentiate between both entities are however lacking.
Objective
Evaluate the thiazide challenge test (TCT) in clinical practice, its aid in clinical decision making, and evaluate the accuracy (sensitivity, specificity) and potentially useful parameters of the TCT.
Methods
Monocentric observational retrospective cohort study from January 2017 to November 2023 in an outpatient Endocrinology department, Ghent University Hospital (Belgium). Twenty-five adult patients with hypercalciuria, elevated parathyroid hormone (PTH), and high-normal or elevated serum calcium underwent a TCT. Outcome measures were serum, urinary biochemical parameters before and after testing, clinical and imaging outcomes, treatment, and follow-up.
Results
Patients with a TCT-based working diagnosis of PHPT show greater increases in albumin-adjusted calcium and total serum calcium concentration than patients with SHPT-IH (+0.11 ± 0.10 vs +0.0071 ± 0.10 mmol/L; P = .025 and +0.14 ± 0.12 vs +0.012 ± 0.15 mmol/L; P = .024, respectively). The TCT-based working diagnosis of PHPT has a sensitivity of 81.8%, a specificity of 77.8%, and a likelihood ratio of 3.68 of estimating a correct final diagnosis. Urinary calcium excretion, PTH, calcium–phosphorous ratio, PTH inhibition rate, and the parathyroid function index do not differ significantly in patients with PHPT compared with those with SHPT-IH.
Conclusion
The TCT aids in discriminating patients with PHPT from those with SHPT-IH based on a rise in serum calcium. Other parameters are not different between both groups. Larger prospective trials are necessary to further define the diagnostic potential of the TCT, its most appropriate biochemical outcome variables, and decision cut-offs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Unit for Osteoporosis and Metabolic Bone Diseases, Ghent University Hospital, 9000 Ghent, Belgium.
- Department of Internal Medicine and Pediatrics, Ghent University, 9000 Ghent, Belgium.
ORCID-Profile: Ewout Verly, Bruno Lapauw, Charlotte Verroken
Zitieren
APA
Verly, E., Lapauw, B., & Verroken, C. (2025). Evaluation of the Thiazide Challenge Test to Differentiate Primary From Hypercalciuria-Related Hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae239
Vancouver
Verly E, Lapauw B, Verroken C. Evaluation of the Thiazide Challenge Test to Differentiate Primary From Hypercalciuria-Related Hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae239
BibTeX
@article{Verly2025,
author = {Verly, Ewout and Lapauw, Bruno and Verroken, Charlotte},
title = {Evaluation of the Thiazide Challenge Test to Differentiate Primary From Hypercalciuria-Related Hyperparathyroidism},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae239}
}
EUVIMED